With Horizon Scanning, we create a complete overview of the new medicines and extensions of indication we expect to be marketed on the Danish market within the next two to three years.
Always has been a matter of timeliness. Mid 2027 earliest?
Danish central procurement agency Amgros has included Blarcamesine in its Horizon Scanning program. Indicates early-stage market access assessment for hospital use pending EMA authorization. Solid sign of institutional readiness in Denmark. Thanks Factanverba on ST